Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic Malignancies

Takehiko Mori, Masatsugu Tanaka, Takeshi Kobayashi, Kazuteru Ohashi, Shin Fujisawa, Akira Yokota, Hiroyuki Fujita, Chiaki Nakaseko, Toru Sakura, Yasuhito Nannya, Satoshi Takahashi, Heiwa Kanamori, Yoshinobu Kanda, Hisashi Sakamaki, Shinichiro Okamoto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although the use of cord blood transplantation (CBT) is increasing, the optimal methods for conditioning and graft-versus-host disease (GVHD) prophylaxis remain to be established. Among previous reports, the Institute of Medical Science, University of Tokyo (IMSUT) has reported remarkably favorable results of CBT for hematologic malignancies as a single-institute experience. The aim of the present multicenter prospective study was to assess the safety and efficacy of CBT performed precisely according to IMSUT transplantation procedures. Thirty-three adult patients with hematologic malignancies, such as acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome, either lacking an HLA-identical sibling/HLA-matched unrelated donor or requiring urgent transplantation were enrolled. Conditioning consisted of total body irradiation (12 Gy), cytarabine, and cyclophosphamide. Cyclosporine A and methotrexate were used for GVHD prophylaxis. Diagnoses were acute leukemia in 26 patients, chronic myelogenous leukemia in 4, and myelodysplastic syndrome in 3; 12 patients were in first complete remission, and the others were in advanced stages at the time of CBT. Thirty-one patients achieved engraftment, and the cumulative incidence of grade II-IV acute GVHD was 45% (95% confidence interval, 28%-62%). With a median follow-up of 46.2 months in 16 surviving patients, the 1-year cumulative incidence of nonrelapse mortality was 15% (95% confidence interval, 5%-30%). Causes of nonrelapse mortality were infection (n = 4) and graft failure (n = 1). The overall and disease-free survival rates were 51% (95% CI, 34%-68%) and 42% (95% CI, 26%-59%), respectively. These results suggest that the IMSUT CBT procedures can safely provide a high disease-free survival rate in patients with high-risk hematologic malignancies.

Original languageEnglish
Pages (from-to)486-491
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number3
DOIs
Publication statusPublished - 2013 Mar

Fingerprint

Hematologic Neoplasms
Fetal Blood
Multicenter Studies
Transplantation
Prospective Studies
Tokyo
Graft vs Host Disease
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease-Free Survival
Leukemia
Survival Rate
Confidence Intervals
Unrelated Donors
Mortality
Whole-Body Irradiation
Cytarabine
Incidence
Conditioning (Psychology)
Methotrexate

Keywords

  • Acute leukemia
  • Graft-versus-host disease
  • Non-relapse mortality
  • Total body irradiation

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic Malignancies. / Mori, Takehiko; Tanaka, Masatsugu; Kobayashi, Takeshi; Ohashi, Kazuteru; Fujisawa, Shin; Yokota, Akira; Fujita, Hiroyuki; Nakaseko, Chiaki; Sakura, Toru; Nannya, Yasuhito; Takahashi, Satoshi; Kanamori, Heiwa; Kanda, Yoshinobu; Sakamaki, Hisashi; Okamoto, Shinichiro.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 3, 03.2013, p. 486-491.

Research output: Contribution to journalArticle

Mori, T, Tanaka, M, Kobayashi, T, Ohashi, K, Fujisawa, S, Yokota, A, Fujita, H, Nakaseko, C, Sakura, T, Nannya, Y, Takahashi, S, Kanamori, H, Kanda, Y, Sakamaki, H & Okamoto, S 2013, 'Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic Malignancies', Biology of Blood and Marrow Transplantation, vol. 19, no. 3, pp. 486-491. https://doi.org/10.1016/j.bbmt.2012.12.007
Mori, Takehiko ; Tanaka, Masatsugu ; Kobayashi, Takeshi ; Ohashi, Kazuteru ; Fujisawa, Shin ; Yokota, Akira ; Fujita, Hiroyuki ; Nakaseko, Chiaki ; Sakura, Toru ; Nannya, Yasuhito ; Takahashi, Satoshi ; Kanamori, Heiwa ; Kanda, Yoshinobu ; Sakamaki, Hisashi ; Okamoto, Shinichiro. / Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic Malignancies. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 3. pp. 486-491.
@article{a46003d041b0474e8504a95ecf736acc,
title = "Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic Malignancies",
abstract = "Although the use of cord blood transplantation (CBT) is increasing, the optimal methods for conditioning and graft-versus-host disease (GVHD) prophylaxis remain to be established. Among previous reports, the Institute of Medical Science, University of Tokyo (IMSUT) has reported remarkably favorable results of CBT for hematologic malignancies as a single-institute experience. The aim of the present multicenter prospective study was to assess the safety and efficacy of CBT performed precisely according to IMSUT transplantation procedures. Thirty-three adult patients with hematologic malignancies, such as acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome, either lacking an HLA-identical sibling/HLA-matched unrelated donor or requiring urgent transplantation were enrolled. Conditioning consisted of total body irradiation (12 Gy), cytarabine, and cyclophosphamide. Cyclosporine A and methotrexate were used for GVHD prophylaxis. Diagnoses were acute leukemia in 26 patients, chronic myelogenous leukemia in 4, and myelodysplastic syndrome in 3; 12 patients were in first complete remission, and the others were in advanced stages at the time of CBT. Thirty-one patients achieved engraftment, and the cumulative incidence of grade II-IV acute GVHD was 45{\%} (95{\%} confidence interval, 28{\%}-62{\%}). With a median follow-up of 46.2 months in 16 surviving patients, the 1-year cumulative incidence of nonrelapse mortality was 15{\%} (95{\%} confidence interval, 5{\%}-30{\%}). Causes of nonrelapse mortality were infection (n = 4) and graft failure (n = 1). The overall and disease-free survival rates were 51{\%} (95{\%} CI, 34{\%}-68{\%}) and 42{\%} (95{\%} CI, 26{\%}-59{\%}), respectively. These results suggest that the IMSUT CBT procedures can safely provide a high disease-free survival rate in patients with high-risk hematologic malignancies.",
keywords = "Acute leukemia, Graft-versus-host disease, Non-relapse mortality, Total body irradiation",
author = "Takehiko Mori and Masatsugu Tanaka and Takeshi Kobayashi and Kazuteru Ohashi and Shin Fujisawa and Akira Yokota and Hiroyuki Fujita and Chiaki Nakaseko and Toru Sakura and Yasuhito Nannya and Satoshi Takahashi and Heiwa Kanamori and Yoshinobu Kanda and Hisashi Sakamaki and Shinichiro Okamoto",
year = "2013",
month = "3",
doi = "10.1016/j.bbmt.2012.12.007",
language = "English",
volume = "19",
pages = "486--491",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic Malignancies

AU - Mori, Takehiko

AU - Tanaka, Masatsugu

AU - Kobayashi, Takeshi

AU - Ohashi, Kazuteru

AU - Fujisawa, Shin

AU - Yokota, Akira

AU - Fujita, Hiroyuki

AU - Nakaseko, Chiaki

AU - Sakura, Toru

AU - Nannya, Yasuhito

AU - Takahashi, Satoshi

AU - Kanamori, Heiwa

AU - Kanda, Yoshinobu

AU - Sakamaki, Hisashi

AU - Okamoto, Shinichiro

PY - 2013/3

Y1 - 2013/3

N2 - Although the use of cord blood transplantation (CBT) is increasing, the optimal methods for conditioning and graft-versus-host disease (GVHD) prophylaxis remain to be established. Among previous reports, the Institute of Medical Science, University of Tokyo (IMSUT) has reported remarkably favorable results of CBT for hematologic malignancies as a single-institute experience. The aim of the present multicenter prospective study was to assess the safety and efficacy of CBT performed precisely according to IMSUT transplantation procedures. Thirty-three adult patients with hematologic malignancies, such as acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome, either lacking an HLA-identical sibling/HLA-matched unrelated donor or requiring urgent transplantation were enrolled. Conditioning consisted of total body irradiation (12 Gy), cytarabine, and cyclophosphamide. Cyclosporine A and methotrexate were used for GVHD prophylaxis. Diagnoses were acute leukemia in 26 patients, chronic myelogenous leukemia in 4, and myelodysplastic syndrome in 3; 12 patients were in first complete remission, and the others were in advanced stages at the time of CBT. Thirty-one patients achieved engraftment, and the cumulative incidence of grade II-IV acute GVHD was 45% (95% confidence interval, 28%-62%). With a median follow-up of 46.2 months in 16 surviving patients, the 1-year cumulative incidence of nonrelapse mortality was 15% (95% confidence interval, 5%-30%). Causes of nonrelapse mortality were infection (n = 4) and graft failure (n = 1). The overall and disease-free survival rates were 51% (95% CI, 34%-68%) and 42% (95% CI, 26%-59%), respectively. These results suggest that the IMSUT CBT procedures can safely provide a high disease-free survival rate in patients with high-risk hematologic malignancies.

AB - Although the use of cord blood transplantation (CBT) is increasing, the optimal methods for conditioning and graft-versus-host disease (GVHD) prophylaxis remain to be established. Among previous reports, the Institute of Medical Science, University of Tokyo (IMSUT) has reported remarkably favorable results of CBT for hematologic malignancies as a single-institute experience. The aim of the present multicenter prospective study was to assess the safety and efficacy of CBT performed precisely according to IMSUT transplantation procedures. Thirty-three adult patients with hematologic malignancies, such as acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome, either lacking an HLA-identical sibling/HLA-matched unrelated donor or requiring urgent transplantation were enrolled. Conditioning consisted of total body irradiation (12 Gy), cytarabine, and cyclophosphamide. Cyclosporine A and methotrexate were used for GVHD prophylaxis. Diagnoses were acute leukemia in 26 patients, chronic myelogenous leukemia in 4, and myelodysplastic syndrome in 3; 12 patients were in first complete remission, and the others were in advanced stages at the time of CBT. Thirty-one patients achieved engraftment, and the cumulative incidence of grade II-IV acute GVHD was 45% (95% confidence interval, 28%-62%). With a median follow-up of 46.2 months in 16 surviving patients, the 1-year cumulative incidence of nonrelapse mortality was 15% (95% confidence interval, 5%-30%). Causes of nonrelapse mortality were infection (n = 4) and graft failure (n = 1). The overall and disease-free survival rates were 51% (95% CI, 34%-68%) and 42% (95% CI, 26%-59%), respectively. These results suggest that the IMSUT CBT procedures can safely provide a high disease-free survival rate in patients with high-risk hematologic malignancies.

KW - Acute leukemia

KW - Graft-versus-host disease

KW - Non-relapse mortality

KW - Total body irradiation

UR - http://www.scopus.com/inward/record.url?scp=84873594732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873594732&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2012.12.007

DO - 10.1016/j.bbmt.2012.12.007

M3 - Article

VL - 19

SP - 486

EP - 491

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 3

ER -